ketamine
Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)
"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
ketamine
Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative
"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."
Spotlight: The State of Sexual Education: State Laws and Regulations Mandating Sexual Education in the United States (Nelson, et al, 2025)
"Although many states mandated sexual education, few required content beyond sexual abstinence, HIV, sexually transmitted infections, and child abuse prevention. Laws that make content optional or facilitate opt-outs can undermine access to this education."
ketamine
Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)
"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."
Spotlight: Psychedelic Sensationalism: An Analysis of the Schedule Classification of Psilocybin (Wood, 2023)
"This paper asserts that drug regulation was used as a form of social control that aimed to stifle the progressive ideals of the youth counterculture movement and reinforce conservative American ideals."
Spotlight: [Exploring and treating complex trauma in everyday clinical reality in child and adolescent psychiatry] (Robin, 2025)
"This report highlights Ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles, where traditional treatments like electroconvulsive therapy often fail."
opioid use disorder
Spotlight: Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression (Manza, et al, 2025)
Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. 3-month timepoint - strong treatment adherence with self-reported depression symptoms decrease
ketamine
Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)
"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "
recovery
Spotlight: Beyond Addiction Sept 19-22 2025
The First Online Conference Focused on
Psychedelic Treatments for Addiction and Long-term Recovery
Spotlight: Is there consciousness beyond the brain? (Goff, 2025)
More:
The Consciousness Issue: The Mystery of Being YouBig Think’s latest special issue journeys to the edges of science
psychedelic research
Spotlight: Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics? (Garcia-Romeu, 2025)
The relative contribution of drug vs. psychological support remains to be determined, though preliminary data indicate the therapeutic relationship can impact treatment outcomes [12], and factors such as environment, personality, and mindset can influence subjective drug effects.
ketamine
Spotlight: A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings (McInnes, et al, 2025)
"In a large real-world sample of 8,136 PTSD patients (87 % with comorbid depression), Ketamine Intravenous Therapy (KIT) significantly reduced PTSD and depression symptoms."
Spotlight: Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions (Rosa, et al, 2025)
"Ketamine and esketamine modulate CB1 receptors and other ECS targets, contributing to their rapid effects. Psilocybin restores 2-AG and enhances CB1 expression in mood-related brain regions, while LSD affects the broader endocannabinoidome in the prefrontal cortex and hippocampus."
cbt
Spotlight: A Conversation About Black Mental Health and How CBT Can Be a Powerful Tool for Healing (2024)
"A growing body of research documents the effectiveness of CBT for racially diverse populations, including Black Americans."
ai therapist
Spotlight: AI Therapist Chatbots
An ineffective, dangerous replacement for human mental health support
ketamine
Spotlight: The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression (2025)
"The reductions in right LB volumes correlate with better clinical responses to ketamine in patients with TRD, suggesting ketamine may exert its effect by attenuating amygdalar overactivity in this population."
ketamine
Spotlight: Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder (Haikazian, et al, 2025)
"Ketamine was determined to be relatively safe, with zero cases of suicidal behaviour and addiction behaviour throughout treatment."
sex therapy
Spotlight: 7 Most Common Sexual Fantasies
from the book "Tell Me What You Want"
